Vericel (VCEL) Non-Current Assets (2010 - 2026)
Vericel's (VCEL) quarterly Non-Current Assets came in at $241.6 million in Q1 2026, up 6.44% year-on-year from $226.9 million in Q1 2025, and little changed quarter-over-quarter from $240.5 million in Q4 2025.
Vericel (VCEL) Non-Current Assets (2010 - 2026) Analysis & Trends
Vericel has disclosed Non-Current Assets across 17 years of filings, most recently posting $241.6 million for Q1 2026.
- Non-Current Assets for Q1 2026 came in at $241.6 million, up 6.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $944.4 million (up 14.31% YoY), and the FY2025 annual result was $240.5 million, up 9.36% from the prior year.
- Non-Current Assets came in at $241.6 million for Q1 2026 at Vericel, roughly flat from $240.5 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $241.6 million in Q1 2026 to a low of $81.6 million in Q3 2022.
- The 5-year median for Non-Current Assets is $166.9 million (2024), against an average of $163.5 million.
- Across the five-year window, Non-Current Assets fell 0.97% in 2023 and soared 90.68% in 2024, its largest moves.
- Vericel's Non-Current Assets stood at $86.1 million in 2022, then soared by 71.85% to $148.0 million in 2023, then jumped by 48.59% to $219.9 million in 2024, then rose by 9.36% to $240.5 million in 2025, then rose by 0.43% to $241.6 million in 2026.
- The last three Non-Current Assets figures came in at $241.6 million (Q1 2026), $240.5 million (Q4 2025), and $231.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Vericel | 2.04 Bn | 1.90 Bn | 49.27 Mn | 241.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 241.56 Mn |
| Dec 31, 2025 | 240.53 Mn |
| Sep 30, 2025 | 231.31 Mn |
| Jun 30, 2025 | 231.03 Mn |
| Mar 31, 2025 | 226.95 Mn |
| Dec 31, 2024 | 219.95 Mn |
| Sep 30, 2024 | 199.89 Mn |
| Jun 30, 2024 | 179.45 Mn |
| Mar 31, 2024 | 166.94 Mn |
| Dec 31, 2023 | 148.03 Mn |
| Sep 30, 2023 | 131.91 Mn |
| Jun 30, 2023 | 127.84 Mn |
| Mar 31, 2023 | 87.55 Mn |
| Dec 31, 2022 | 86.14 Mn |
| Sep 30, 2022 | 81.64 Mn |
| Jun 30, 2022 | 89.72 Mn |
| Mar 31, 2022 | 88.41 Mn |
| Dec 31, 2021 | 85.24 Mn |
| Sep 30, 2021 | 79.20 Mn |
| Jun 30, 2021 | 83.43 Mn |